L19-IL2 Immunocytokine in Combination with the Anti-Syndecan-1 46F2SIP Antibody Format: A New Targeted Treatment Approach in an Ovarian Carcinoma Model.

Cancers (Basel) · 2019 · PMC6769537 · PMID 31443604

Europe PMC DOI

hedged sentence

0.0006

closest p · 0.0× alpha

0.0006

boldest claim

The sentences

extremely significantp = 0.0006actually significant

At day 14, compared to untreated group the two-tailed p values of 46F2SIP and L19-IL2 groups were very significant ( p = 0.0041, p = 0.0047) and for 46F2SIP/L19-IL2 group were extremely significant ( p = 0.0006), indicating the strong efficacy of combined therapy.

also in 7,787 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.